Brexpiprazole
- Generic Name
- Brexpiprazole
- Brand Names
- Rxulti, Rexulti
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O2S
- CAS Number
- 913611-97-9
- Unique Ingredient Identifier
- 2J3YBM1K8C
- Background
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to aripiprazole, brexpiprazole has different binding affinities for dopamine and seroton...
- Indication
Brexpiprazole is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. It is also indicated for the treatment of schizophrenia in patients 13 years of age and older.
...
- Associated Conditions
- Agitation, Schizophrenia, Major Depressive Disorder (MDD)
- Associated Therapies
- -
Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
- Conditions
- Interventions
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2018-06-12
- Target Recruit Count
- 24
- Registration Number
- NCT03292848
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸Alliance for Wellness dba Alliance for Research, Long Beach, California, United States
🇺🇸Cutting Edge Research Group, Oklahoma City, Oklahoma, United States
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2020-08-17
- Target Recruit Count
- 381
- Registration Number
- NCT03287869
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇧🇬"Mental Health Centre-Ruse" EOOD, Male department for persons with severe mental disorders, Female department for persons with severe mental disorders, Ruse, Bulgaria
🇵🇱Indywidualna Specjalistyczna Praktyka Lekarska Wieslaw Jerzy Cubala, Gdańsk, Poland
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 322
- Registration Number
- NCT03259555
- Locations
- 🇺🇸
Galiz Research, Hialeah, Florida, United States
🇺🇸Ci Trials, Riverside, California, United States
🇺🇸Richard H Weisler, MD, PA, and Associates, Raleigh, North Carolina, United States
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2020-02-11
- Target Recruit Count
- 333
- Registration Number
- NCT03257865
- Locations
- 🇺🇸
CiTrials, Santa Ana, California, United States
🇺🇸Research Centers of America LLC, Hollywood, Florida, United States
🇺🇸CNRI-San Diego, San Diego, California, United States
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-10-17
- Target Recruit Count
- 296
- Registration Number
- NCT03238326
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Kinston, North Carolina, United States
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT03149991
- Locations
- 🇺🇸
Massachusetts General Hospital, Depression Clinical and Research Program, Boston, Massachusetts, United States
🇺🇸Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2021-12-08
- Target Recruit Count
- 336
- Registration Number
- NCT03033069
- Locations
- 🇺🇸
Investigational Site, Everett, Washington, United States
A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Duke University
- Target Recruit Count
- 15
- Registration Number
- NCT02934932
- Locations
- 🇺🇸
Pamela Smith, Durham, North Carolina, United States
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- H. Lundbeck A/S
- Registration Number
- NCT02758067
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
- Conditions
- Interventions
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.